In October, breast cancer awareness is extra important. Our Phase II #ClinicalTrial is evaluating how our potential treatment impacts #TNBC patients when used in combination with #chemotherapy and #immunotherapy. Learn more: bit.ly/3juRfLK. #BCAM

While #BreastCancer research has made great improvements over the past two decades, the disease is still a major threat worldwide. During #BCAM, we hope to spread awareness of our #TNBC #ClinicalTrial: bit.ly/3juRfLK

#ScienceSunday: From NBCF, #TNBC means that the three most common types of receptors known to fuel most #BreastCancer growth are not present in the tumor, requiring a different treatment path. Click to learn about our #ClinicalTrial for those with TNBC: bit.ly/3juRfLK

How are you supporting #BCAM awareness initiatives? We have an easy way to help! Please share our #ClinicalTrial for those living with #TNBC: bit.ly/3juRfLK

At Infinity, we’re proud to support Breast Cancer Awareness Month! We’re dedicated to advancing #TNBC treatments. Find out more about our #BreastCancer clinical trial here: bit.ly/3juRfLK. #BCAM

Support for #TNBC patients is needed all year long, but #BCAM highlights the importance of awareness, education and research during the month of October. We encourage you to share information about our MARIO-3 #ClinicalTrial with those who might qualify: bit.ly/3juRfLK

While #BCAM is almost over, we are dedicated to spread awareness all year long. Learn more about our Phase II #ClinicalTrial for those living with #TNBC: bit.ly/3juRfLK

Infinity Announces the Date of Its Third Quarter Financial Results Conference Call and Webcast businesswire.com/news/home/2020…

Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium businesswire.com/news/home/2020… #breastcancer #eganelisib #patientsarewaiting

Infinity Pharmaceuticals Presents Front-Line Triple Negative Breast Cancer Data from Ongoing Phase 2 MARIO-3 Trial at the 2020 San Antonio Breast Cancer Symposium businesswire.com/news/home/2020…

Infinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer businesswire.com/news/home/2021… #patientsarewaiting #eganelisib #mUC

Infinity Pharmaceuticals to Participate in Three Investor Conferences This Month businesswire.com/news/home/2021…

Infinity Pharmaceuticals Announces MARIO-275 Phase 2 Data in Patients with Advanced Urothelial Cancer to be Presented at ASCO Genitourinary Cancers Symposium businesswire.com/news/home/2021…

Infinity congratulates co-founder Dr. Eric Lander, Eric Lander, on his appointment as Presidential Science Advisor and Director of the Office of Science and Technology Policy. We share President Biden’s and Dr. Lander’s commitment to great science. #Scienceisback

Infinity to Present at the H.C. Wainwright Global Life Sciences Conference businesswire.com/news/home/2021…

Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast businesswire.com/news/home/2021…

Infinity to Present at the Oppenheimer & Co. Annual Healthcare Conference businesswire.com/news/home/2021…

Join us on Thursday, May 13, 2021 at 4:30 PM ET for our First Quarter 2021 Financial Results Conference Call and Webcast. businesswire.com/news/home/2021…

Please join us for our KOL Event: MARIO-3 TNBC Study Update and MARIO-275 UC Status Update featuring Dr. Erika Hamilton and Consulting Chief Physician, Dr. Schwartz. A Q&A session will follow the event. Register here: lifesci.events/INFI

Infinity Announces the Date of Its Third Quarter 2021 Financial Results Conference Call and Webcast ~ November 2, 2021, at 4:30 p.m. businesswire.com/news/home/2021…